Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Revenue (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Revenue for 7 consecutive years, with $13.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 2.21% to $13.6 million in Q4 2025 year-over-year; TTM through Nov 2025 was $87.4 million, a 60.28% increase, with the full-year FY2025 number at $84.0 million, up 53.95% from a year prior.
  • Revenue was $13.6 million for Q4 2025 at Nurix Therapeutics, up from $11.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $44.1 million in Q2 2025 to a low of $5.0 million in Q1 2021.
  • A 5-year average of $14.4 million and a median of $12.3 million in 2024 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 60.58% in 2024, then surged 264.34% in 2025.
  • Nurix Therapeutics' Revenue stood at $7.4 million in 2021, then fell by 8.29% to $6.8 million in 2022, then surged by 123.49% to $15.2 million in 2023, then fell by 12.37% to $13.3 million in 2024, then grew by 2.21% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Revenue are $13.6 million (Q4 2025), $11.3 million (Q3 2025), and $44.1 million (Q2 2025).